- Home
- MIRA vs SBFM Comparison
MIRA vs SBFM Comparison
Compare MIRA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- SBFM
- Stock Information
- Founded
- MIRA 2020
- SBFM 2006
- Country
- MIRA United States
- SBFM United States
- Employees
- MIRA N/A
- SBFM N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- SBFM Health Care
- Exchange
- MIRA Nasdaq
- SBFM Nasdaq
- Market Cap
- MIRA 25.2M
- SBFM 6.7M
- IPO Year
- MIRA 2023
- SBFM N/A
- Fundamental
- Price
- MIRA $1.47
- SBFM $1.92
- Analyst Decision
- MIRA
- SBFM Strong Buy
- Analyst Count
- MIRA 0
- SBFM 1
- Target Price
- MIRA N/A
- SBFM $7.00
- AVG Volume (30 Days)
- MIRA 8.6M
- SBFM 1.6M
- Earning Date
- MIRA 11-11-2025
- SBFM 11-12-2025
- Dividend Yield
- MIRA N/A
- SBFM N/A
- EPS Growth
- MIRA N/A
- SBFM N/A
- EPS
- MIRA N/A
- SBFM N/A
- Revenue
- MIRA N/A
- SBFM $36,341,741.00
- Revenue This Year
- MIRA N/A
- SBFM $32.20
- Revenue Next Year
- MIRA N/A
- SBFM $32.74
- P/E Ratio
- MIRA N/A
- SBFM N/A
- Revenue Growth
- MIRA N/A
- SBFM 19.22
- 52 Week Low
- MIRA $0.73
- SBFM $1.17
- 52 Week High
- MIRA $2.56
- SBFM $3.90
- Technical
- Relative Strength Index (RSI)
- MIRA 53.10
- SBFM 60.67
- Support Level
- MIRA $1.35
- SBFM $1.50
- Resistance Level
- MIRA $2.45
- SBFM $2.43
- Average True Range (ATR)
- MIRA 0.15
- SBFM 0.16
- MACD
- MIRA 0.03
- SBFM 0.04
- Stochastic Oscillator
- MIRA 17.92
- SBFM 44.36
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.